NCT02932514Unknown不适用
Home Use Sensor (HOUSE) Study
Senseonics, Inc.2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2016年10月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Accuracy of Eversense CGM System for Arm and Abdomen Sensors compared to SMBG Meter as determined by Mean Absolute Relative Difference (MARD) calculations.
研究概览
简要总结
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense Continuous Glucose Monitoring System (Eversense System) measurements when compared with a Self-monitoring blood glucose (SMBG) meter. The investigation will assess device performance in two insertion locations (abdomen and upper arm), evaluate safety of the Eversense System usage, and assess the usability of the Eversense system in the hands of user at home setting. Changes in HbA1c from baseline will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult subjects, age ≥18 years
- •Clinically confirmed diagnosis of diabetes mellitus for ≥1 year and using insulin by subcutaneous injection or insulin pump.
- •Subject has signed an informed consent form and is willing to comply with protocol requirements
排除标准
- •Female subjects of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study
- •A condition preventing or complicating the placement, operation or removal of the sensor or wearing of transmitter, including upper extremity deformities or skin condition
- •Symptomatic coronary artery disease; unstable angina; myocardial infarction, transient ischemic attack or stroke within 6 months; uncontrolled hypertension (systolic>160 mm HG or diastolic >100 mm Hg at time of screening); current congestive heart failure; history of cardiac arrhythmia (benign PACs and PVCs allowed). Subjects with asymptomatic coronary artery disease (e.g., CABG, stent placement or angioplasty) may participate if negative stress test within 1 year prior to screening and written clearance from cardiologist documented.
- •History of hepatitis B, hepatitis C, or HIV
- •Currently receiving (or likely to need during the study period): immunosuppressant therapy; chemotherapy; anticoagulant/antithrombotic therapy (excluding aspirin); glucocorticoids (excluding ophthalmic or nasal). This exclusion does include the use of inhaled glucocorticoids and the use of topical glucocorticoids (over sensor site only); antibiotics for chronic infection (e.g. osteomyelitis, endocarditis)
- •A condition requiring or likely to require magnetic resonance imaging (MRI)
- •Known topical or local anesthetic allergy
- •Known allergy to glucocorticoids
- •Any condition that in the investigator's opinion would make the subject unable to complete the study or would make it not in the subject's best interest to participate in the study. Conditions include, but are not limited to, psychiatric conditions, known current or recent alcohol abuse or drug abuse by subject history, a condition that may increase the risk of induced hypoglycemia or risk related to repeated blood testing. Investigator will supply rationale for exclusion
- •Participation in another clinical investigation (drug or device) within 2 weeks prior to screening or intent to participate during the study period
- •The presence of any other active implanted device*
研究组 & 干预措施
Eversense (Senseonics) CGM System
Experimental
干预措施: Eversense (Senseonics) Continuous Glucose Monitoring System (Device)
结局指标
主要结局
Accuracy of Eversense CGM System for Arm and Abdomen Sensors compared to SMBG Meter as determined by Mean Absolute Relative Difference (MARD) calculations.
时间窗: 180 Days
Usability of the Eversense CGM System over 180 days will be evaluated through Study Questionnaires.
时间窗: 180 days
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
A research study to check the feasibility of contineous ECG monitoring at home using a wearable ECG DeviceCTRI/2019/01/017347Waferchips Techno solutions Pvt Ltd
招募中
不适用
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced FeaturesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes MellitusNCT05131139Senseonics, Inc.350
已完成
不适用
Home Monitoring of Patients With Chronic Diseases - an eRehab Test-retest StudyArthritis, RheumatoidNCT02316977Eva Ejlersen Wæhrens200
撤回
不适用
Clearblue Advanced Fertility Monitor Consumer Three Cycle at Home StudyPregnancyNCT02535260SPD Development Company Limited
已完成
不适用
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 DaysDiabetes MellitusDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT03808376Senseonics, Inc.208